A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high grade undifferentiated uterine sarcoma (HGUS) after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment

Ray-Coquard, I. L.; Tos, A.P.i. De; Coens, C.; Huizing, M.; Herráez, A. Casado; Westermann, Anneke M.; Bompas, Emmanuelle; Earl, HM; Hensley, Martee L.; Negrouk, Anastassia; Reed, Nicholas

doi:10.1093/annonc/mdw388.27

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We identified eight ongoing or recently completed trials for cabozantinib as a single agent and in combination regimens for patients with soft tissue sarcomas, including five phase 2 trials (Table 2 [56,57] or patients with multiple tumor types, such as alveolar soft part sarcoma, clear cell sarcoma, leiomyosarcoma, rhabdomyosarcoma, and synovial sarcoma [58,59,60 & ,61-63]. Most of these trials are in their initial phase.…”

Section: Soft Tissue Sarcomasmentioning

confidence: 99%

Cabozantinib as an emerging treatment for sarcoma

Schöffski

Blay

2020

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose of reviewSarcomas are a diverse group of rare solid tumors with limited treatment options for patients with advanced, inoperable disease. Cabozantinib is a tyrosine kinase inhibitor currently approved for advanced renal cell, hepatocellular, and medullary thyroid carcinoma. Cabozantinib has potent activity against a variety of kinases, including MET, vascular endothelial growth factor receptor, and AXL, that are associated with sarcoma growth and development. Here we review the preclinical findings and clinical development of cabozantinib in the treatment of soft tissue sarcoma, gastrointestinal stromal tumors (GIST), osteosarcoma, and Ewing sarcoma. Recent findingsIn vitro, cabozantinib has shown relevant activity in inhibiting the growth and viability of soft tissue sarcoma, GIST, osteosarcoma, and Ewing sarcoma tumor cell lines. Cabozantinib also promoted the regression of GIST in various murine xenografts, including imatinib-resistant models. More than 10 prospective trials with cabozantinib that included patients with sarcomas have been completed or are currently ongoing. Clinical activity with cabozantinib has been recently reported in phase 2 clinical trials for patients with GIST and for patients with osteosarcoma or Ewing sarcoma. SummaryCabozantinib has shown promising activity for the treatment of various sarcomas, supporting further evaluation in this setting.

show abstract

Section: Soft Tissue Sarcomasmentioning

confidence: 99%